Syngene concludes acquisition of biologics facility from Stelis Biopharma
The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs 617 crores adjusted…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Stelis Biopharma
Syngene to acquire multi-modal facility from Stelis Biopharma
Adds 20,000 liters of installed biologics drug substance manufacturing capacity, with scope for further expansion, and a high…
Stelis Biopharma’s facility receives EIR from USFDA
Establishment Inspection Report (EIR) from USFDA received for the drug-device combination to be commercialised from the company's…
Stelis Biopharma gets EU cGMP accreditation for two biologics manufacturing facilities
GMP approval was received both for the flagship facility and small-scale commercial and clinical batch manufacturing facility
Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabs
The Drugs Controller General of India (DCGI) had granted emergency use permission to Sputnik Light, subject to certain regulatory…
RDIF, Stelis Biopharma join hands for 200 mn doses of Sputnik V vaccine
The parties intend to commence supplies from the Q3 of 2021
Stelis concludes $195 million Series B and Series C fund raise
Post money valuation for Stelis after Series C fund raise pegged at ~$350 million
HDFC founder, Aditya Puri joins Strides Group as Advisor and Director of Stelis Biopharma
He has the distinction of having been the longest-serving head of a private bank in India
Strides Board approves incremental investments in Stelis
It will accelerate Strides’ re-entry into sterile injectables business post the completion of the Company’s non-compete period in…
Strides Shasun biotech arm receives $8.49 million investment from GMS Holdings
Further equity infusion by GMS Pharma (Singapore) will be made in tranches based on the project and product development needs over…